Sarepta Therapeutics (NASDAQ:SRPT) surged about 5.4% after the FDA accepted supplemental NDAs for full approval of exon 45- and 53-amenable Duchenne drugs Amondys 45 and Vyondys 53, targeting a Feb. 28, 2027 decision that could lift confirmatory-study requirements.

Previous Week Recap

  • FDA Accepts SNDAs For Full Approval: Sarepta said FDA accepted SNDAs for full approval of Duchenne drugs Amondys 45 and Vyondys 53, setting a Feb 28, 2027 target decision; approval would remove ongoing confirmatory-study requirements.
  • Analysts See Positive Exon 45/53 Path: Sarepta (SRPT) jumped about 5.4% intraday after FDA accepted filings for exon 45- and exon 53-amenable Duchenne programs, with analysts calling the acceptance a positive sign for the regulatory path.

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.